Literature DB >> 17179125

Linezolid-induced optic neuropathy: a mitochondrial disorder?

M Javaheri1, R N Khurana, T M O'hearn, M M Lai, A A Sadun.   

Abstract

We report a case of bilateral mitochondrial optic neuropathies secondary to long-term linezolid treatment, show the nature of recovery, review the findings in the literature and propose a potential mitochondrial mechanism for linezolid-induced mitochondrial optic neuropathy. This is an observational case report and literature review with presentation of the clinical course of linezolid mitochondrial optic neuropathies through clinical and psychophysical documentation. Main outcome measures included: visual acuity, funduscopical examinations and peripapillary retinal nerve fibre layer (PRNFL) optical coherence tomography (OCT). A 6-year-old boy presented with bilateral optic neuropathies secondary to 1 year of linezolid treatment for osteomyelitis of the mandible. On presentation, visual acuities were 20/400 in both eyes, with considerable optic disc oedema, hyperaemia and PRNFL swelling confirmed by OCT. 2 weeks after the discontinuation of linezolid, visual acuities returned to 20/25 in both eyes, with reduction in the optic disc oedema, hyperaemia and PRNFL swelling. 3 months after the discontinuation of linezolid treatment, visual acuities were stable at 20/20 in both eyes, with a marked decrease in PRNFL swelling confirmed by OCT, and the development of mild temporal optic disc pallor in both eyes. Doctors should be aware of impairments of vision among patients on long-term linezolid treatment and promptly discontinue treatment to prevent irreversible vision loss. The development and resolution of bilateral optic neuropathies with considerable PRNFL swelling in this patient provide insight into the more general rubric of mitochondrial optic neuropathies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17179125      PMCID: PMC1857552          DOI: 10.1136/bjo.2006.102541

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  30 in total

1.  Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy.

Authors:  Alfredo A Sadun; Valerio Carelli; Solange R Salomao; Adriana Berezovsky; Peter A Quiros; Federico Sadun; Anna Maria DeNegri; Rafael Andrade; Milton Moraes; Angelo Passos; Patrícia Kjaer; Josenilson Pereira; Maria Lucia Valentino; Stan Schein; Rubens Belfort
Journal:  Am J Ophthalmol       Date:  2003-08       Impact factor: 5.258

2.  Mitochondrial function and dysfunction within the optic nerve.

Authors:  Alfredo A Sadun; Valerio Carelli
Journal:  Arch Ophthalmol       Date:  2003-09

3.  Severe bilateral optic neuritis associated with prolonged linezolid therapy.

Authors:  Frédéric Frippiat; Christelle Bergiers; Claire Michel; Jean-Pierre Dujardin; Geneviève Derue
Journal:  J Antimicrob Chemother       Date:  2004-04-29       Impact factor: 5.790

Review 4.  Metabolic optic neuropathies.

Authors:  Alfredo A Sadun
Journal:  Semin Ophthalmol       Date:  2002-03       Impact factor: 1.975

5.  Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration.

Authors:  Richard G Fiscella; Wico W Lai; Bruce Buerk; Mona Khan; Keith A Rodvold; Jose S Pulido; Sami Labib; Michael J Shapiro; Norman P Blair
Journal:  Ophthalmology       Date:  2004-06       Impact factor: 12.079

Review 6.  Peripheral neuropathy associated with prolonged use of linezolid.

Authors:  Adam M Bressler; Shanta M Zimmer; Jane L Gilmore; Jyoti Somani
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

7.  Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Authors:  Mary C Birmingham; Craig R Rayner; Alison K Meagher; Susan M Flavin; Donald H Batts; Jerome J Schentag
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

8.  Effect of corticosterone treatment on mitochondrial oxidative energy metabolism in developing rat brain.

Authors:  S S Katyare; Sureshkumar Balasubramanian; D V Parmar
Journal:  Exp Neurol       Date:  2003-09       Impact factor: 5.330

9.  Linezolid-associated toxic optic neuropathy: a report of 2 cases.

Authors:  Elsie Lee; Susanne Burger; Jilan Shah; Christine Melton; Michael Mullen; Floyd Warren; Robert Press
Journal:  Clin Infect Dis       Date:  2003-10-17       Impact factor: 9.079

Review 10.  Mitochondrial dysfunction as a cause of optic neuropathies.

Authors:  Valerio Carelli; Fred N Ross-Cisneros; Alfredo A Sadun
Journal:  Prog Retin Eye Res       Date:  2004-01       Impact factor: 21.198

View more
  25 in total

1.  Antibiotic-induced neurotoxicity.

Authors:  Shamik Bhattacharyya; Ryan Darby; Aaron L Berkowitz
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 2.  Pharmacological issues of linezolid: an updated critical review.

Authors:  Antonello Di Paolo; Paolo Malacarne; Emanuele Guidotti; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

Review 3.  [Optic disc swelling : A compilation of relevant differential diagnoses].

Authors:  V Prokosch; D C Dragnea; S Pitz
Journal:  Ophthalmologe       Date:  2016-11       Impact factor: 1.059

Review 4.  Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components.

Authors:  Alison E Barnhill; Matt T Brewer; Steve A Carlson
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

5.  Linezolid-induced optic neuropathy with a rare pathological change in the inner retina.

Authors:  Nobuhito Ishii; Reiko Kinouchi; Masatomo Inoue; Akitoshi Yoshida
Journal:  Int Ophthalmol       Date:  2016-02-12       Impact factor: 2.031

6.  Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.

Authors:  Shawn Flanagan; Edward E McKee; Debaditya Das; Paul M Tulkens; Hiromi Hosako; Jill Fiedler-Kelly; Julie Passarell; Ann Radovsky; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

7.  Use of linezolid in neonatal and pediatric inpatient facilities--results of a retrospective multicenter survey.

Authors:  A Simon; E Müllenborn; M Prelog; W Schenk; J Holzapfel; F Ebinger; A Klabunde-Cherwon; J Faber; A H Groll; K Masjosthusmann; C Dohna-Schwake; K Beutel; E Dirkwinkel; T Lehrnbecher; R A Ammann; A Müller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-03       Impact factor: 3.267

8.  Lack of neuropathological changes in rats administered tedizolid phosphate for nine months.

Authors:  Michael J Schlosser; Hiromi Hosako; Ann Radovsky; Mark T Butt; Dragomir Draganov; Jenifer Vija; Frederick Oleson
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

9.  Capreomycin-induced optic neuritis in a case of multidrug resistant pulmonary tuberculosis.

Authors:  Rahul Magazine; Mahuya Pal; Bharti Chogtu; Veena Nayak
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

10.  Linezolid-associated optic neuropathy in a patient with ocular sarcoidosis.

Authors:  Katsuji Kiuchi; Miki Miyashiro; Chiemi Kitagawa; Sanae Wada
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.